Calixarenes as new platforms for drug design

Calixarenes, macrocyclic compounds of phenolic units linked by methylene groups at the 2,6-positions, present some of the requirements to serve as platforms for the design and synthesis of biological active compounds. They are also interesting host molecules for chemical biology study purposes. Thei...

Full description

Saved in:
Bibliographic Details
Published in:Current drug discovery technologies Vol. 6; no. 2; p. 151
Main Authors: de Fátima, Angelo, Fernandes, Sergio Antonio, Sabino, Adão Aparecido
Format: Journal Article
Language:English
Published: United Arab Emirates 01-06-2009
Subjects:
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Calixarenes, macrocyclic compounds of phenolic units linked by methylene groups at the 2,6-positions, present some of the requirements to serve as platforms for the design and synthesis of biological active compounds. They are also interesting host molecules for chemical biology study purposes. Their basic molecular scaffold has potential ability for molecule recognition; it is promptly synthesized in large amounts, and might be easily modified for maximizing molecular interactions toward relevant guest molecules. Calixarenes present well-defined conformational properties and cavities with molecular dimensions that enable to encapsulate guest drugs. Calixarenes have been shown to have antiviral, antibacterial, antifungal, and anticancer activities (including HIV as target). We provide here an overview of the use of calixarenes either as new chemical entity of distinct biological activities or as host for bioactive guest molecules. The importance of calixarenes for drugs development is discussed. The use of Nuclear Magnetic Resonance (NMR) and Mass Spectrometry (MS) techniques for the study of calixarenes as biological molecule hosts is also described.
AbstractList Calixarenes, macrocyclic compounds of phenolic units linked by methylene groups at the 2,6-positions, present some of the requirements to serve as platforms for the design and synthesis of biological active compounds. They are also interesting host molecules for chemical biology study purposes. Their basic molecular scaffold has potential ability for molecule recognition; it is promptly synthesized in large amounts, and might be easily modified for maximizing molecular interactions toward relevant guest molecules. Calixarenes present well-defined conformational properties and cavities with molecular dimensions that enable to encapsulate guest drugs. Calixarenes have been shown to have antiviral, antibacterial, antifungal, and anticancer activities (including HIV as target). We provide here an overview of the use of calixarenes either as new chemical entity of distinct biological activities or as host for bioactive guest molecules. The importance of calixarenes for drugs development is discussed. The use of Nuclear Magnetic Resonance (NMR) and Mass Spectrometry (MS) techniques for the study of calixarenes as biological molecule hosts is also described.
Author Sabino, Adão Aparecido
de Fátima, Angelo
Fernandes, Sergio Antonio
Author_xml – sequence: 1
  givenname: Angelo
  surname: de Fátima
  fullname: de Fátima, Angelo
  email: adefatima@qui.ufmg.br
  organization: Grupo de Estudos em Química Orgânica e Biológica (GEQOB), Departamento de Química, ICEx, UFMG, Avenida Presidente Antônio Carlos, 6627, Campus Pampulha, Belo Horizonte, MG, 31270-901, Brazil. adefatima@qui.ufmg.br
– sequence: 2
  givenname: Sergio Antonio
  surname: Fernandes
  fullname: Fernandes, Sergio Antonio
– sequence: 3
  givenname: Adão Aparecido
  surname: Sabino
  fullname: Sabino, Adão Aparecido
BackLink https://www.ncbi.nlm.nih.gov/pubmed/19519339$$D View this record in MEDLINE/PubMed
BookMark eNo1jstKAzEYRrOo2Iu-gAvJAzj6_7lnKYM3KLhp1yUxSRmZSYekRX17R9TNd-AsDt-SzPIhR0KuEG4ZanGHUgMqDlYbI4zhwGZk8SObyZo5Wdb6DsCsVuaczNFKtJzbBblpXd99uhJzrNRVmuMHHXt3TIcyVDotDeW0pyHWbp8vyFlyfY2Xf1yR7ePDpn1u1q9PL-39uvFT89iwIDSLjEMSKSiGIKVzQYQkUUlgKiYUCYM0CN4qxb2V4s16CdwZ4BrZilz_dseTH2LYjaUbXPna_d9m36n3Qss
CitedBy_id crossref_primary_10_1007_s10847_012_0161_5
crossref_primary_10_1039_c0cc05662f
crossref_primary_10_1039_C1NJ20636B
crossref_primary_10_3390_pharmaceutics11060292
crossref_primary_10_1007_s10847_013_0372_4
crossref_primary_10_1016_j_antiviral_2010_09_009
crossref_primary_10_1016_j_tet_2022_132816
crossref_primary_10_1016_S1004_9541_13_60628_X
crossref_primary_10_1080_00268976_2017_1347295
crossref_primary_10_1111_jam_13658
crossref_primary_10_1002_anie_201206785
crossref_primary_10_1016_j_tet_2012_09_032
crossref_primary_10_1016_j_bbamcr_2013_07_010
crossref_primary_10_1016_j_cplett_2017_12_023
crossref_primary_10_1039_c3ob40927a
crossref_primary_10_1002_jps_23681
crossref_primary_10_1021_cr500392w
crossref_primary_10_1111_j_1742_4658_2011_08045_x
crossref_primary_10_1080_10406638_2015_1033432
crossref_primary_10_1016_j_ejmech_2020_112984
crossref_primary_10_1080_00958972_2011_616930
crossref_primary_10_2174_1389557522666220928120727
crossref_primary_10_1007_s10847_014_0412_8
crossref_primary_10_1016_j_cclet_2014_03_012
crossref_primary_10_1016_j_mycmed_2022_101254
crossref_primary_10_1080_10426507_2012_743147
crossref_primary_10_1016_j_bmc_2011_10_031
crossref_primary_10_1016_j_cplett_2016_01_022
crossref_primary_10_36306_konjes_1039091
crossref_primary_10_1016_j_bioorg_2019_103207
crossref_primary_10_1186_2193_8865_3_72
crossref_primary_10_1016_j_bmc_2009_11_016
crossref_primary_10_1016_j_saa_2014_04_156
crossref_primary_10_1039_C4OB02611J
crossref_primary_10_1039_C2CS35233H
crossref_primary_10_15407_bioorganica2022_01_086
crossref_primary_10_3109_01480545_2011_653490
crossref_primary_10_1002_slct_202002881
crossref_primary_10_1080_10610278_2012_761342
crossref_primary_10_4155_ppa_2017_0034
crossref_primary_10_1007_s11743_016_1792_0
crossref_primary_10_1002_masy_201600101
crossref_primary_10_1007_s10847_010_9825_1
crossref_primary_10_1002_slct_201701306
crossref_primary_10_1016_j_colsurfb_2012_10_045
crossref_primary_10_1080_00304948_2017_1320903
crossref_primary_10_1002_ange_201206785
crossref_primary_10_1007_s10847_018_0814_0
crossref_primary_10_1016_j_tet_2015_07_077
crossref_primary_10_1021_jp204154m
crossref_primary_10_1080_10406638_2023_2212106
crossref_primary_10_1111_cbdd_12267
crossref_primary_10_1002_ijch_201100040
crossref_primary_10_1016_j_bmc_2012_01_041
crossref_primary_10_1111_cbdd_12818
crossref_primary_10_1016_j_arabjc_2016_04_007
crossref_primary_10_1021_jp507151r
crossref_primary_10_1039_C2CC16480A
crossref_primary_10_1016_j_tetlet_2011_08_142
crossref_primary_10_1016_j_bmc_2023_117586
crossref_primary_10_1016_j_arabjc_2016_06_013
crossref_primary_10_1039_C9RA03354H
crossref_primary_10_1007_s10847_011_0062_z
crossref_primary_10_1007_s10847_015_0581_0
crossref_primary_10_1016_j_ejps_2012_07_015
crossref_primary_10_1002_chem_201605246
crossref_primary_10_1134_S1070428014040228
crossref_primary_10_17721_fujcV3I2P93_100
crossref_primary_10_1021_jp102471c
crossref_primary_10_17721_fujcV5I2P49_55
crossref_primary_10_1021_acsinfecdis_9b00290
crossref_primary_10_1039_C5SM01891A
crossref_primary_10_1080_10426507_2012_741164
crossref_primary_10_1186_s40543_017_0111_3
crossref_primary_10_15406_jnmr_2015_02_00028
crossref_primary_10_1039_C7CS00040E
crossref_primary_10_1007_s10847_012_0169_x
crossref_primary_10_1021_cr200213s
crossref_primary_10_1039_C6CE02649D
crossref_primary_10_1016_j_bmcl_2013_08_040
crossref_primary_10_1039_c2ob06730g
crossref_primary_10_1039_C5RA05423K
crossref_primary_10_1002_cbic_201800609
crossref_primary_10_1007_s10847_017_0773_x
crossref_primary_10_14710_jksa_25_3_123_129
crossref_primary_10_1007_s00706_021_02736_4
crossref_primary_10_1016_j_jmgm_2018_06_018
crossref_primary_10_1039_c2nj40338b
crossref_primary_10_1080_10406638_2018_1464037
crossref_primary_10_1016_j_saa_2014_10_100
crossref_primary_10_1002_cplu_201200141
crossref_primary_10_1016_j_molliq_2017_09_113
crossref_primary_10_1002_chem_201100154
crossref_primary_10_1002_hlca_201200044
crossref_primary_10_1007_s10847_020_01022_w
crossref_primary_10_1016_j_cellsig_2024_111174
crossref_primary_10_1039_C8QO00728D
crossref_primary_10_17721_fujcV7I2P61_67
crossref_primary_10_1002_ardp_201400390
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.2174/157016309788488302
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
ExternalDocumentID 19519339
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GroupedDBID ---
.5.
0R~
29F
4.4
53G
5GY
AAEGP
ABEEF
ABVDF
ACGFS
ACITR
ACIWK
ACPRK
AFRAH
AGJNZ
ALMA_UNASSIGNED_HOLDINGS
ANTIV
C1A
CGR
CS3
CUY
CVF
DU5
EBS
ECM
EIF
EJD
F5P
GH2
HZ~
IPNFZ
KCGFV
NPM
O9-
P2P
RIG
ID FETCH-LOGICAL-b339t-2d472e230f4fd621055aad4df5165026ef14f1d5810b9663b954c9b503a803712
ISSN 1570-1638
IngestDate Thu May 23 23:13:43 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-b339t-2d472e230f4fd621055aad4df5165026ef14f1d5810b9663b954c9b503a803712
PMID 19519339
ParticipantIDs pubmed_primary_19519339
PublicationCentury 2000
PublicationDate 2009-Jun
PublicationDateYYYYMMDD 2009-06-01
PublicationDate_xml – month: 06
  year: 2009
  text: 2009-Jun
PublicationDecade 2000
PublicationPlace United Arab Emirates
PublicationPlace_xml – name: United Arab Emirates
PublicationTitle Current drug discovery technologies
PublicationTitleAlternate Curr Drug Discov Technol
PublicationYear 2009
References Curr Drug Discov Technol. 2009 Dec;6(4):306
References_xml
SSID ssj0029768
Score 2.223597
SecondaryResourceType review_article
Snippet Calixarenes, macrocyclic compounds of phenolic units linked by methylene groups at the 2,6-positions, present some of the requirements to serve as platforms...
SourceID pubmed
SourceType Index Database
StartPage 151
SubjectTerms Calixarenes - chemical synthesis
Calixarenes - chemistry
Drug Delivery Systems
Drug Design
Magnetic Resonance Spectroscopy
Mass Spectrometry
Title Calixarenes as new platforms for drug design
URI https://www.ncbi.nlm.nih.gov/pubmed/19519339
Volume 6
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1La8JAEF60vfRS-n6XPRQvGppNNiY5Fqt4aRG00Jsk2V2x4INGof77zuyah5aW9tDLEnbDsGYmk2_GmW8JuRO-_u67lu0qbnEhpQUwJLYkT3yIPqLY0zzb3b7__Bo8tnm7Usmj_nzuXzUNc6Br7Jz9g7ZzoTAB16BzGEHrMP5K79hs9YEdXjLFM2QANeNJ0QvEppp6oS7el6O6KAo33jbpR83yOE2wthOgaZZ6LxUbClnv6D_Y2WI8MXlZLI2dbeemtYmAMxqNZ0hSAN4jv6UfQURuOmyEFuXCLVgMn4zFbCMTERYVU5nz9G0L8V3ZuzZLRuSUPCUzPLPbHhwjJEwmgCiQhE0mAbgYV3dlL0rqm0-0_liICNTQIf28usWqnS1VSRUwEsLo1lMeqANE0y2U2e8xzVa4tfuvG9O0s0bYVmiiIcrggOyvYwv6YIzikFTk9IjUeoacfNWgg6LXLm3QGu0VtOWrY9IoWQ6NUgqWQ3PLoTBSNA1qLOeEvHTag1bXWp-lYcWwsYXlCO47EuJNxZVoOngsahQJLpTH4F11mlIxrpjwAmbHEAG7cejxJIw9240CZHV0TsnOdDaV54RKL44B-CRh4gseRn6oAGLaLHHtgLNEuRfkzDyF4dwQpgyz53P57coV2Sss6prsKngb5Q2ppmJ5q3XzCWeDToQ
link.rule.ids 782
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Calixarenes+as+new+platforms+for+drug+design&rft.jtitle=Current+drug+discovery+technologies&rft.au=de+F%C3%A1tima%2C+Angelo&rft.au=Fernandes%2C+Sergio+Antonio&rft.au=Sabino%2C+Ad%C3%A3o+Aparecido&rft.date=2009-06-01&rft.issn=1570-1638&rft.volume=6&rft.issue=2&rft.spage=151&rft_id=info:doi/10.2174%2F157016309788488302&rft_id=info%3Apmid%2F19519339&rft_id=info%3Apmid%2F19519339&rft.externalDocID=19519339
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1570-1638&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1570-1638&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1570-1638&client=summon